In many regulatory territories, patients with Crohn disease (CD) who lose response to adalimumab at a dose of 40 mg given every other week may be given an escalation to 40 mg every week. However, in Japan, where adalimumab is typically administered by a healthcare provider rather than by the patient, a study investigated the efficacy, safety, and pharmacokinetics (PK) of adalimumab after a dose escalation to 80 mg every other week as a means to reduce the need for additional patient appointments.
In many regulatory territories, patients with Crohn disease (CD) who lose response to adalimumab at a dose of 40 mg given every other week may be given an escalation to 40 mg every week. However, in Japan, where adalimumab is typically administered by a healthcare provider rather than by the patient, a study investigated the efficacy, safety, and pharmacokinetics (PK) of adalimumab after a dose escalation to 80 mg every other week as a means to reduce the need for additional patient appointments.
The phase 3, multicenter, open-label, single-arm, 52-week study enrolled 28 patients, 25 of whom completed week 8, and 18 of whom completed week 52. All patients in the primary efficacy population were taking at least 1 concomitant medication during the study, including immunosuppressants, corticosteroids, and aminosalicylate.
At week 8, the proportion of patients who achieved a 50-point reduction in the Crohn Disease Activity Index (CR50) was 75.0%. The proportion of patients achieving CR50 was maintained from 67.9% at week 4 through 57.1% at week 52.
C-reactive protein (CRP) levels also decreased throughout the study period. The median change from baseline in CRP at week 8 was −0.390 mg/dL (range: −5.56 to 2.99). The proportion of patients with a 50% or greater reduction in CRP from baseline grew from 21.4% at week 4 to 46.4% at week 16, then remained steady through week 52.
In the PK assessment, the mean concentration of adalimumab at week 52 was 11.7 (±5.31) μg/mL in the 10 patients who achieved remission and 6.68 (±4.11 μg/mL) in the 8 patients who did not. One patient became positive for anti-drug antibodies during the study period.
A total of 24 patients reported at least 1 adverse event (AE), with nasopharyngitis being the most commonly reported AE. Four patients discontinued the study due to AEs.
The authors concluded that, in this patient population, dose escalation of adalimumab to 80 mg every other week was able to restore and maintain response through week 52, and no new safety concerns were identified with this dosing strategy.
Reference
Motoya S, Watanabe M, Wallace K, et al. Efficacy and safety of dose escalation to adalimumab 80 mg every other week in Japanese patients with Crohn’s disease who lost response to maintenance therapy. Inflam Intest Dis. 2018;2(4):228-235. doi: 10.1159/000486786.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.